Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025)

Candel Therapeutics has disclosed Accumulated Expenses across 6 years of filings, most recently posting $3.4 million for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $3.4 million, up 11.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.4 million (up 11.39% YoY), and the FY2025 annual result was $3.4 million, up 11.39% from the prior year.
• Accumulated Expenses came in at $3.4 million for Q4 2025 at Candel Therapeutics, down from $5.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.1 million in Q3 2025 to a low of $1.0 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $3.2 million (2024), against an average of $3.0 million.
• Across the five-year window, Accumulated Expenses surged 243.08% in 2022 and plunged 63.24% in 2025, its largest moves.
• Candel Therapeutics' Accumulated Expenses stood at $2.1 million in 2021, then surged by 125.33% to $4.7 million in 2022, then declined by 7.77% to $4.4 million in 2023, then slumped by 30.26% to $3.0 million in 2024, then grew by 11.39% to $3.4 million in 2025.
• The last three Accumulated Expenses figures came in at $3.4 million (Q4 2025), $5.1 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.